ECSP088209A - Nueva forma cristalina de un derivado de piridazino[4,5-b]indol - Google Patents

Nueva forma cristalina de un derivado de piridazino[4,5-b]indol

Info

Publication number
ECSP088209A
ECSP088209A EC2008008209A ECSP088209A ECSP088209A EC SP088209 A ECSP088209 A EC SP088209A EC 2008008209 A EC2008008209 A EC 2008008209A EC SP088209 A ECSP088209 A EC SP088209A EC SP088209 A ECSP088209 A EC SP088209A
Authority
EC
Ecuador
Prior art keywords
piridazino
indol
derivative
crystal form
new crystal
Prior art date
Application number
EC2008008209A
Other languages
English (en)
Inventor
John D Higgins
William L Rocco
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088209(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of ECSP088209A publication Critical patent/ECSP088209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describe una nueva forma cristalina de 7-cloro-N,N,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida, procesos para preparar dicha forma cristalina de 7-cloro-N,N,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida, composiciones que comprenden dicha forma mezclada con uno o más excipientes farmacéuticamente aceptables, y usos para la misma.
EC2008008209A 2005-08-29 2008-02-20 Nueva forma cristalina de un derivado de piridazino[4,5-b]indol ECSP088209A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71215305P 2005-08-29 2005-08-29
PCT/US2006/033254 WO2007027525A1 (en) 2005-08-29 2006-08-24 Novel crystalline form of a pyridazino [4 , 5-b] indole derivative

Publications (1)

Publication Number Publication Date
ECSP088209A true ECSP088209A (es) 2008-06-30

Family

ID=37546937

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008209A ECSP088209A (es) 2005-08-29 2008-02-20 Nueva forma cristalina de un derivado de piridazino[4,5-b]indol

Country Status (31)

Country Link
US (1) US7683062B2 (es)
EP (1) EP1924585B1 (es)
JP (1) JP5063600B2 (es)
KR (2) KR20080050577A (es)
CN (1) CN101253176B (es)
AR (1) AR057099A1 (es)
AT (1) ATE531717T1 (es)
AU (1) AU2006285142B2 (es)
BR (1) BRPI0615259A2 (es)
CA (1) CA2619284C (es)
CR (1) CR9723A (es)
CY (1) CY1112317T1 (es)
DK (1) DK1924585T3 (es)
EA (1) EA014164B1 (es)
EC (1) ECSP088209A (es)
ES (1) ES2375841T3 (es)
HR (1) HRP20120073T1 (es)
IL (1) IL189276A (es)
MA (1) MA30000B1 (es)
NO (1) NO20081365L (es)
NZ (1) NZ566087A (es)
PL (1) PL1924585T3 (es)
PT (1) PT1924585E (es)
RS (1) RS52318B (es)
SI (1) SI1924585T1 (es)
TN (1) TNSN08059A1 (es)
TW (1) TW200813060A (es)
UA (1) UA91716C2 (es)
UY (1) UY29771A1 (es)
WO (1) WO2007027525A1 (es)
ZA (1) ZA200801890B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545968C (en) * 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
US20070249827A1 (en) * 2004-06-02 2007-10-25 Sandoz Ag Meropenem Intermediatein in Crystalling Form
EA018698B1 (ru) * 2005-09-21 2013-10-30 4Сц Аг Сульфонилпирролгидрохлориды как ингибиторы гистондезацетилазы
EP2404911A1 (en) * 2005-10-31 2012-01-11 Janssen Pharmaceutica NV Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
NZ576347A (en) * 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
AU2009283039A1 (en) * 2008-08-18 2010-02-25 Sanofi-Aventis U.S. Llc Process for preparing polymorph of 7-chloro-N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4H-pyridazin0[4,5-b]indole-1-acetamide
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
KR20130101524A (ko) * 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
CA2980801A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途
WO2026130526A1 (zh) * 2024-12-20 2026-06-25 杭州百新生物医药科技有限公司 三元稠环类化合物及其医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2829939B3 (fr) 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
US20050220881A1 (en) 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
KR20130087059A (ko) 2013-08-05
TNSN08059A1 (en) 2009-07-14
US7683062B2 (en) 2010-03-23
US20080139569A1 (en) 2008-06-12
KR20080050577A (ko) 2008-06-09
EP1924585A1 (en) 2008-05-28
JP5063600B2 (ja) 2012-10-31
MA30000B1 (fr) 2008-12-01
AR057099A1 (es) 2007-11-14
WO2007027525A1 (en) 2007-03-08
UY29771A1 (es) 2007-03-30
NZ566087A (en) 2011-03-31
PL1924585T3 (pl) 2012-08-31
PT1924585E (pt) 2012-01-19
AU2006285142A1 (en) 2007-03-08
CA2619284A1 (en) 2007-03-08
CY1112317T1 (el) 2015-12-09
CN101253176B (zh) 2012-04-18
CN101253176A (zh) 2008-08-27
JP2009506116A (ja) 2009-02-12
RS52318B (sr) 2012-12-31
IL189276A (en) 2012-07-31
UA91716C2 (ru) 2010-08-25
NO20081365L (no) 2008-04-03
HK1123794A1 (en) 2009-06-26
TW200813060A (en) 2008-03-16
DK1924585T3 (da) 2012-02-27
BRPI0615259A2 (pt) 2011-05-17
EA014164B1 (ru) 2010-10-29
CR9723A (es) 2008-06-18
HRP20120073T1 (hr) 2012-07-31
IL189276A0 (en) 2008-08-07
ZA200801890B (en) 2009-11-25
AU2006285142B2 (en) 2012-06-14
ATE531717T1 (de) 2011-11-15
SI1924585T1 (sl) 2012-09-28
ES2375841T3 (es) 2012-03-06
EA200800716A1 (ru) 2008-08-29
EP1924585B1 (en) 2011-11-02
CA2619284C (en) 2014-04-29

Similar Documents

Publication Publication Date Title
CR9723A (es) Nueva forma cristalina de un derivado de piridazino[4,5-b] indol
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
NO20082793L (no) Nye tiofenderivater
CL2008002539A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
MY147949A (en) Hydrogenated benzo[c]thiophene derivatives as immunomodulators
NO20083630L (no) Nye pyridinderivater
NO20091395L (no) Nye tiofenderivater
ECSP10010129A (es) Inhibidores de quinasas símil polo
ECSP12011935A (es) Triazolopiridinas
EA200970273A1 (ru) Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила
DK1888584T3 (da) Tricykliske 1,6-dihydro- 1,3,5,6-tetraaza-as-indacen-baserede forbindelser og farmaceutiske sammensætninger omfattende samme som hæmmere af IKK-enzymaktivitet
AR047928A1 (es) Derivados de tetrahidropiridoindol
CL2007002188A1 (es) Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal.
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
CL2008002540A1 (es) Compuestos derivados aza-indol-2,3-sustituidos; composicion farmaceutica; y uso ene l tratamiento de una infeccion viral.
TW200700406A (en) Novel thiophene derivatives
EA200970851A1 (ru) Еженедельное введение ингибиторов дипептидилпептидазы
CL2009000512A1 (es) Compuestos heterociclicos sustituidos derivados de imidazo[4,5-d]piridazina, imidazo[4,5-c]piridazina, imidazo[4,5d]pirimidina, entre otros; composicion farmaceutica que comprende a dichos comppuestos; y uso para tratar el virus de la hepatitis c.
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
SV2006002473A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales ref. 2005.893 (806.671)
UY29099A1 (es) Fenilaminotiazoles sustituidos y su uso
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
CL2011001078A1 (es) Compuestos derivados de espirodihidrotetraazabenzoazuleno; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o tratamiento de dismenorrea, disfuncion sexual, hipertension, cirrosis hepatica y esquizofrenia entre otras.